

IRON

Diagnostic reagent for determination of Iron concentration.

Liquid. Dual reagents. Store at +2/+8°C. For in Vitro Diagnostic Use (IVD). **Do not freeze.**

Ref No	Pack
MH-202	75 mL

Changes made in the instructions for use are marked as grey.

INTENDED USE

The test is applied for the quantitative determination of iron concentration in human serum and plasma.

GENERAL INFORMATION

Iron (Fe) is involved in the functioning of all cells. Depending on the oxidation status, it is available in ferrous (Fe^{+2}) or ferric (Fe^{+3}) form. It mostly binds to iron-protoporphyrin (heme) acting as an enzyme co-factor and iron-sulfur (Fe-S) clusters.¹ Hemoproteins play parts on many biological functions such as oxygen binding and carrying (hemoglobins), oxygen metabolism (catalases, peroxidases), cellular respiration and electron transport (cytochromes). In addition, non-heme iron-containing proteins are vital for the fundamental cellular processes such as DNA synthesis, cell proliferation and differentiation, gene regulation, drug metabolism and steroid synthesis.² Furthermore, ferrous iron (Fe^{+2}) may cause damage by catalyzing the formation of highly reactive hydroxyl radicals ($\cdot\text{OH}$) from hydrogen peroxide, named as "Fenton reaction".³ These hydroxyl radicals harm cell membranes, proteins and DNA.¹ Iron has to circulate bound to plasma transferrin in order to provide highly insoluble Fe^{+3} to the cells via transferrin receptor. Iron can be stored in ferritin and hemosiderin form in the cells.⁴ Although stored iron can be mobilized for re-use under normal circumstances, only small amounts of iron is available other than this physiological "storage".¹

Many diseases stem from the instability in iron homeostasis. Too much iron accumulates in anemia associated with hereditary hemochromatosis and iron overload. Adequate amount of iron is not available for heme synthesis in iron deficiency anemia (IDA). In chronic disease anemia (CDA), iron is re-distributed to the macrophages in order to increase resistance against infections.⁵

Control of the iron homeostasis acts both at cellular and systematic level, and contains a complex system consisting of different types of cells, carriers and signals.

The connection between cells absorbing iron from diet (duodenal enterocytes), cells consuming iron (mainly erythroid precursors) and cells storing iron (hepatocytes

and tissue macrophages) is strictly regulated for maintaining systemic iron homeostasis.¹ Hepsidine, a B-defensin-like antimicrobial peptide, is thought to be a regulator adjusting the iron absorption and macrophage iron emission.⁶ Hepsidine is synthesized in the liver as a result of the changes in the body's iron need such as anemia, hypoxia and inflammation, and is released into the circulation. It induces the internalization and deterioration of ferroportin, a vital cellular iron-carrying protein in the membrane of macrophages and basolateral area of enterocytes.^{7,8} The expression of the proteins playing a role in uptaking, storing and releasing of the iron is determined with the cell's iron need and is regulated at post-transcriptional level by iron regulatory protein and iron responsive element (IRP/IRE) network.⁹

Most of the Fe in the body (3 – 5 g) is present in the heme-containing proteins carrying and storing oxygen, including hemoglobin (2,5 g) and myoglobin (130 mg). Small amounts (150 mg) are incorporated into enzymes with active sites containing heme or Fe-sulfur clusters, including peroxidases, catalases, ribonucleotide reductase and enzymes of the Krebs cycle and electron transport chain. Most of the non-heme Fe (1 g in adult men) is stored as ferritin or hemosiderin in macrophages and hepatocytes. Only a small amount of Fe (3 mg) is bound to the transferrin in circulation.¹ Each milliliter of blood contains 0,4 – 0,5 mg Fe included in Hb. For this reason, 2,5 g Fe is present as a part of Hb in an adult man.^{10,11}

Cellular Fe exceeding immediate needs is stored in a partially deteriorated ferritin form known as Fe oxide and hemosiderin in ferritin nanocavity.¹²

About half of estimated 1 billion people with anemia worldwide have iron deficiency (ID).¹³⁻¹⁵ ID is a disease particularly seen in the children and pre-menopausal women in low- and middle-income countries, however, it can be seen in men, in people of all ages and in developed countries.¹⁶⁻¹⁸ ID stem from physiologically increasing iron need for dietary iron for growth and development in children quite often,¹⁷ and almost always from chronic blood loss or pregnancy in adults, particularly in pre-menopausal women.¹⁸ There is a correlation between iron status as well as depression and neurocognitive function in children.^{19,20} ID also affects immune function and infection sensitivity.^{21,22} Iron supplementation has been reported to

reduce the fatigue in non-anemic women with low ferritin levels,^{23,24} provide benefit to the exercise performance of women with ID²⁵ and lessen the restless leg syndrome.²⁶ Oral iron use in children cures anemia and may improve cognitive performance in older children, but the evidences of its effects on cognitive development in younger children lack.^{17,27,28} Anemia of chronic disease (ACD), also known as inflammation anemia, is a disorder of iron distribution. It is common in the patients with infectious and inflammatory diseases, including chronic kidney disease, inflammatory bowel disease, chronic heart failure, malignancies and liver diseases.²⁹⁻³³ Iron overload is typically subtle and can cause progressive and sometimes even irreversible tissue damage prior to the formation of clinical symptoms. Iron overload disorders can be categorized according to whether underlying pathophysiological defect is in hepsidine-ferroportin axis, erythroid development or iron transport.^{1,34} Iron overload may occur due to the transfusion of multiple erythrocydes and parenteral iron supplementation.¹

TEST PRINCIPLE

Ferrozine method

At acidic pH, Fe in the serum to be measured is cleaved from transferrin and reduced from ferric (Fe⁺³) to ferrous (Fe⁺²) form. It then reacts with the chromogenic ferrozine in reagent 2 to form Fe-chromogen complexes. The absorbance of this complex, which can be measured spectrophotometrically at 560 nm, is proportional to the Fe concentration in the sample.

REAGENT COMPONENTS

Reagent 1:

Acetate buffer
Hydroxylamine hydrochloride ≤ 220 mmol/L

Reagent 2:

Ferrozine ≤ 15 g/L
Buffer
Antibacteriel

REAGENT PREPARATION

Reagents are ready for use.

REAGENT STABILITY AND STORAGE

Reagents are stable at +2/+8°C till the expiration date stated on the label which is only for closed vials.

Once opened vials are stable for 30 days at +2/+8°C in optimum conditions. On board stability is strongly related to auto analyzers' cooling specification and carry-over values.

Reagent stability and storage data have been verified by using Clinical and Laboratory Standards Institute (CLSI) EP25-A protocol.³⁵

SAMPLE REQUIREMENTS

Serum and plasma can be used and are collected according to the standard procedures. For plasma, sample collection tubes with Li heparin should be preferred. Sample collection tubes with EDTA must not be preferred for plasma. Hemolyzed samples must not be used.

Iron activity stability in serum and plasma^{54,58}:

7 days at +20/+25°C
3 weeks at +2 /+8°C
1 year at -20°C

CALIBRATION AND QUALITY CONTROL

Calibration: The assay requires the use of an Iron-Magnesium Standard or Arcal Auto Calibrator.

Iron-Magnesium Standard

Ref.No: VT-031

Arcal Auto Calibrator

Ref.No: VT-003

Calibration stability is 30 days. Calibration stability depends on the application characteristics and cooling capacity of the autoanalyzer used.

Control: Commercially available control material with established values determined by this method can be used. We recommend:

Arcon N Level 1 Control- Lyophilized
Ref.No: VT-001

Arcon P Level 2 Control- Lyophilized
Ref.No: VT-002

At least two level controls must be run once in every 24 hours. Each laboratory should determine its own quality control scheme and procedures. If quality control results are not within acceptable limits, calibration is required.

REFERENCE INTERVALS / MEDICAL DECISION LEVELS

Serum/Plasma⁵³:

Women : 50 – 170 µg/dL
Men : 65 – 175 µg/dL

Note: Plasma Fe shows a large biological variation in healthy subjects. The individual daily variation of Fe is approximately 25% to 30%.³⁶⁻⁴⁰ Furthermore, serum Fe concentration has diurnal variation, and is generally highest in the morning and lowest in the evening.⁴⁰⁻⁴²

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary, determine its own reference range.

Reference interval data have been verified by using CLSI EP28-A3c protocol.⁴³

PERFORMANCE CHARACTERISTICS

Measuring Interval

According to CLSI EP34-ED1:2018, "Measuring Interval" refers to the interval where the analyte concentration is measured with intended accuracy in terms of medical and laboratory requirements without dilution, concentrating or any kind of pre-treatment that is between the analyte's lower limit of quantitation (LLoQ) and upper limit of quantitation (ULoQ).⁴⁴

The determined analytic measuring interval for Iron is 5 - 1000 µg/dL

Detection Capability

Limit of Detection (LoD): 3 µg/dL

Limit of Quantitation (LoQ): 5 µg/dL

Note: LoQ values are based on Coefficient of Variation Percentage (CV) ≤ 20%.

LoD and LoQ values have been verified by using CLSI EP17-A2:2012 protocol.⁴⁵

Linearity

This method shows measurement linearity in the activities up to 1000 µg/dL. Autoanalyzer's auto-dilution system can be used if the concentrations have higher values. See device manual for further information.

For the manual dilution procedure, dilute the sample 1:10 using 0.90% isotonic. After this process, multiply the result of the reworked sample by the dilution factor. Do not report the sample result after dilution if it is marked as lower than the linear lower limit. Rerun with a suitable dilution.

Linearity Studies data have been verified by using CLSI EP06-A:2003 protocol.⁴⁶

Precision

Running system has been developed according to 20x2x2 "The Single Site" protocol. Repeatability and Within-Laboratory Precision/Within-Device values have been obtained according to the running results.

According to the protocol in use, 2 separate runs per day have been made for 20 days (no obligation for being consecutive days). This protocol has been applied to each low and high samples separately and 80 results have been obtained for each one. Statistically, the results have been obtained using 2-factor Nested-ANOVA model.⁴⁷

Repeatability (Within Run) and Repeatability (Day to Day) SD and CV% values of Iron have been given in the table 1 and 2 respectively.

Table 1. Iron Repeatability (Within Run) results obtained from samples in two different concentrations

Mean Concentration	SD*	CV%	n
63 µg/dL	0.90	1.43	80
204 µg/dL	0.96	0.47	80

*SD: Standard Deviation

Note: This working system has been named "Within-Run Precision" in the previous CLSI - EP05-A2 manual.⁴⁸

Table 2. Iron Repeatability (Day to Day) results obtained from samples in two different concentrations

Mean Concentration	SD	CV%	n
63 µg/dL	1.12	1.77	80
204 µg/dL	4.15	2.03	80

Note: This working system has been named "Total Precision" in the previous CLSI - EP05-A2 manual.⁴⁸

Method Comparison

As a result of the statistical evaluation of the method comparison data:

r=0.991

Passing-Bablok equation:⁴⁹

y= 1.03x + 0.15 µg/dL

Interference

Endogenous interferant and analyte concentrations that have been used in the Iron scanning tests has been determined according to "CLSI EP37-ED1:2018" and "CLSI EP07-ED3:2018" manuals.^{50,51}

The total acceptable error rate, which is going to be used to detect whether the observed differential value obtained from Iron interference scanning test is appropriate, is determined as ±10%.⁵²

In Iron test results, no significant interaction has been observed in the determined endogenous interferant and analyte concentrations or between interferants and analyte. Due to the interference with hemolyzed samples is high, such samples should be rejected for Iron testing.

Interferant-Concentration	Iron Target (µg/dL)	N*	Observed Recovery %
Bilirubin 48 mg/dL	78,8	3*	102
Lipemi 1336 mg/dL	69,8	3*	104
Copper 1425 µg/dL	46	3*	96

* Total acceptable error rate determined as interference limit and repeatability (within run) pre-detected for the related method were used for the calculations of how many times the control and test samples prepared as a serum pool are going to be run repetitively. In the calculations, the accepted error rate for type 1 (α error) was 5% and for type 2 (β error) was 10% (90% power).⁵¹

Note 1: Since intravenous iron preparations and iron chelators bind iron much more loosely than iron-binding dyes, chromogen binding iron tests often measure iron in circulating iron preparations and chelates as well, leading to falsely high iron concentrations.⁵⁵⁻⁵⁷

It should be noted that endogenous interferants, as well as various medicines and metabolites, anticoagulants (e.g. Heparin, EDTA, citrate, oxalate) and preservatives (e.g. sodium fluoride, iodoacetate, hydrochloride acids) such as additives, materials that may contact with samples during collection and processing (serum separator devices, sample collection containers and contents, catheters, catheter wash solutions, skin disinfectants, hand cleaners and lotions, glass washing detergents, powder gloves), dietary substances known to affect some specific tests (caffeine, beta-carotene, poppy seeds, etc.), or some substances present in a sample that cause foreign proteins (heterophilic antibodies, etc.), autoimmune response (autoantibodies, etc.), or due to malignancy (for example, interference by paraproteins with phosphate testing and indirect ion selective electrode methods) may show some negative effects that will cause various attempts and some misjudgements.⁵¹

These performance characteristics have been obtained using an autoanalyzer. Results may vary slightly when using different equipment or manual procedures.

WARNINGS AND PRECAUTIONS

IVD: For in Vitro Diagnostic use only.

Do not use expired reagents.

Reagents with two different lot numbers should not be interchanged.

For professional use.

Follow Good Laboratory Practice (GLP) guidelines.

CAUTION: Human source samples are processed with this product. All human source samples must be treated as potentially infectious materials and must be handled in accordance with OSHA standards.

Danger

EUH032 :Releases a very toxic gas if contacts with acid.

H317 :May cause allergic skin reaction.

Precaution

P280 :Use protective gloves / clothes / glasses / mask.

P264 :Wash your hands properly after using.

P272 :Contaminated work clothes should not be allowed to be used outside of the workplace.

Intervention

P302+P352 :Wash with plenty of water and soap if it contacts with skin.

P333+P313 :Seek medical help if it irritates your skin or develops rash.

P362+P364 :Remove contaminated clothes and wash properly before using.

Disposal

P501 :Dispose the vials and contents according to the local regulations.

REFERENCES

- Rifai, N., Chiu, R. W., & Young, I., et al., (2023) Tietz Textbook of Laboratory Medicine (7th ed.), Chapter 40: Iron Metabolism, p.418-e40, Elsevier, St. Louis, Missouri 63043
- Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. *Biochemistry* 2012;51:5705–24.
- Koppenol WH. The centennial of the Fenton reaction. *Free Radic Biol Med* 1993;15:645–51.
- Torti FM, Torti SV. Regulation of ferritin genes and protein. *Blood* 2002;99:3505–16.
- Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. *Science* 2012;338:768–72.
- Ganz T. Hepcidin and iron regulation, 10 years later. *Blood* 2011;117:4425–33.
- Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004;306:2090–3.
- Ganz T. Systemic iron homeostasis. *Physiol Rev* 2013;93:1721–41.
- Kuhn LC. Iron regulatory proteins and their role in controlling iron metabolism. *Metallomics* 2015;7:232–43.
- Finch C. Regulators of iron balance in humans. *Blood* 1994;84:1697–702.
- Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. *Blood* 1986;68:726–31.
- Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. *Biochim Biophys Acta* 2009;1790:589–99.
- Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, et al. A systematic analysis of global anemia burden from 1990 to 2010. *Blood* 2014;123:615–24.
- Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, Pena-Rosas JP, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population representative data. *Lancet Glob Health* 2013;1:e16–25.
- WHO, UNICEF, UNU. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva, World Health Organisation 2001;WHO/NHD/01.3. Available at http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/.
- Camaschella C. Iron-deficiency anemia. *N Engl J Med*
















- 2015;372:1832–43.
17. +Pasricha SR, Drakesmith H, Black J, Hipgrave D, Biggs BA. Control of iron deficiency anemia in low- and middle-income countries. *Blood* 2013;121:2607–17.
 18. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. *Am J Clin Nutr* 2000;72:257S–64S.
 19. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. *Lancet* 1996;348:992–6.
 20. Beard JL, Hendricks MK, Perez EM, Murray-Kolb LE, Berg A, Vernon-Feagans L, Irlam J, et al. Maternal iron deficiency anemia affects postpartum emotions and cognition. *J Nutr* 2005;135:267–72.
 21. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. *J Nutr* 2001;131:568S–79S; discussion 580S.
 22. Ahluwalia N, Sun J, Krause D, Mastro A, Handte G. Immune function is impaired in iron-deficient, homebound, older women. *Am J Clin Nutr* 2004;79:516–21.
 23. DeLoughery TG. Microcytic anemia. *N Engl J Med* 2014;371:2537.
 24. Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. *Eur J Haematol* 2015.
 25. Pasricha SR, Low M, Thompson J, Farrell A, De-Regil LM. Iron supplementation benefits physical performance in women of reproductive age: a systematic review and meta-analysis. *J Nutr* 2014;144:906–14.
 26. Avni T, Reich S, Lev N, Gafter-Gvili A. Iron supplementation for restless legs syndrome - A systematic review and metaanalysis. *Eur J Intern Med* 2019;63:34–41.
 27. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. *Lancet* 2021;16:233–48.
 28. Low M, Farrell A, Biggs BA, Pasricha SR. Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials. *CMAJ* 2013;185:E791–802.
 29. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, et al. Iron deficiency in chronic heart failure: an international pooled analysis. *Am Heart J* 2013;165:575–82 e573.
 30. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I, British Committee for Standards in H. Guideline for the laboratory diagnosis of functional iron deficiency. *Br J Haematol* 2013;161:639–48.
 31. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005;352:1011–23.
 32. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, Gomollon F, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. *Inflamm Bowel Dis* 2007;13:1545–53.
 33. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. *Blood* 2019;133:40–50.
 34. Fleming RE, Ponka P. Iron overload in human disease. *N Engl J Med* 2012;366:348–59
 35. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline. CLSI Document EP25-A. Wayne, PA: CLSI; 2009.
 36. Pilon VA, Howanitz PJ, Howanitz JH, Domres N. Day-to-day variation in serum ferritin concentration in healthy subjects. *Clin Chem* 1981;27:78–82.
 37. Borel MJ, Smith SM, Derr J, Beard JL. Day-to-day variation in iron-status indices in healthy men and women. *Am J Clin Nutr* 1991;54:729–35.
 38. Maes M, Bosmans E, Scharpe S, Hendriks D, Cooremans W, Neels H, De Meyer F, et al. Components of biological variation in serum soluble transferrin receptor: relationships to serum iron, transferrin and ferritin concentrations, and immune and haematological variables. *Scand J Clin Lab Invest* 1997;57:31–41.
 39. Statland BE, Winkel P. Relationship of day-to-day variation of serum iron concentrations to iron-binding capacity in healthy young women. *Am J Clin Pathol* 1977;67:84–90.
 40. Dallman PR. Diagnosis of anemia and iron deficiency: analytic and biological variations of laboratory tests. *Am J Clin Nutr* 1984;39:937–41.
 41. Hershko C, Bar-Or D, Gaziel Y, Naparstek E, Konijn AM, Grossowicz N, Kaufman N, et al. Diagnosis of iron deficiency anemia in a rural population of children. Relative usefulness of serum ferritin, red cell protoporphyrin, red cell indices, and transferrin saturation determinations. *Am J Clin Nutr* 1981;34:1600–10.
 42. Ridefelt P, Larsson A, Rehman JU, Axelsson J. Influences of sleep and the circadian rhythm on iron-status indices. *Clin Biochem* 2010;43:1323–8.
 43. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition. CLSI Document EP28-A3c. Wayne, PA: CLSI; 2010.
 44. Clinical and Laboratory Standards Institute (CLSI). Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking – 1st Edition. CLSI Document EP34. Wayne, PA: CLSI; 2018.
 45. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition. CLSI Document EP17-A2. Wayne, PA: CLSI; 2012.
 46. Clinical and Laboratory Standards Institute (CLSI).
 47. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach - 1st Edition. CLSI Document EP06-A. Wayne, PA: CLSI; 2003.
 48. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition. CLSI Document EP05-A3. Wayne, PA: CLSI; 2014.
 49. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition. CLSI Document EP05-A2. Wayne, PA: CLSI; 2004.
 50. Bablok W et al. A General Regression Procedure for Method Transformation. *J Clin Chem Clin Biochem* 1988;26:783-790.
 51. Clinical and Laboratory Standards Institute (CLSI).

- Supplemental Tables for Interference Testing in Clinical Chemistry - First Edition. CLSI Document EP37. Wayne, PA: CLSI; 2018.
52. Clinical and Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry - Third Edition. CLSI Document EP07. Wayne, PA: CLSI; 2018.
 53. CLIA proficiency testing criteria for acceptable analytical performance, as printed in the Federal Register July 11, 2022;87(131:41194-242.
 54. Wu AHB, editor. Tietz Clinical Guide to Laboratory Tests. 4th ed. St. Louis, MO: Elsevier Saunders; 2006
 55. Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2: Jan 2002.
 56. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999;45:898–901.
 57. Huisman W. Interference of imferon in colorimetric assays for iron. Clin Chem 1980;26:635–7.
 58. Ikuta K, Ito S, Tanaka H, Sasaki K, Torimoto Y, Fujiya M, Kohgo Y. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy. Clin Chim Acta 2011;412:2261–6
 59. Guder WG, Narayanan S, Wisser H, et al. List of Analytes; Preanalytical Variables. Brochure in: Samples: From the Patient to the Laboratory. Darmstadt: GIT-Verlag 1996.



Archem Sağlık Sanayi ve Tic. A.Ş. (With official contract based manufacturing agreement with Validity Sağlık Hiz. Sanayi A.Ş. Company)
 Mahmutbey Mah. Halkalı Cad. No:124 Kat:4
 Bağcılar/İstanbul/Türkiye
 Tel: + 90 212 444 08 92
 Fax: +90 212 629 98 89
 info@archem.com.tr www.archem.com.tr
 info@validity.com.tr www.validity.com.tr



SYMBOLS	
	In Vitro Diagnostic Medical Device
	Lot Number
	Reagent 1
	Reagent 2
	Global Trade Item Number
	Reference Number
	Good Laboratory Practices
	Identifies Products to Be Used Together
	Product of Turkey
	Manufacturer
	Expiration Date
	Temperature Limits
	Consult Instructions for Use
	Caution
	Number of Tests